MRNA SEC Filings: 8-K, 10-Q, S-3 & 424B – Moderna

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 31, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 1, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 20, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 1, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Moderna Reports Third Quarter 2026 Financial Results, Raises Full-Year Revenue Growth Outlook to 15%-25%

Nov 6, 2026

8-K

Moderna Adds Chief Operating Officer Role as Company Expands into Oncology and Juan Andres Returns

Sep 30, 2026

8-K

Moderna Announces Proposed Private Placement of $2.0 Billion in Convertible Senior Notes

Sep 1, 2026

8-K

Moderna Reports Second Quarter 2026 Financial Results and Business Updates

Jul 31, 2026

8-K

Moderna Appoints Former Biogen CFO Michael McDonnell to Board of Directors

Jul 8, 2026

8-K

Moderna, Inc. Announces Results of 2026 Annual Meeting and By-Law Amendment

May 11, 2026

Prospectus

TYPE

HEADLINE

FILED AT

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 20, 2026

SC TO-I/A

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]

Dec 16, 2025

SC TO-I/A

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]

Nov 18, 2025

SC TO-I

Form SC TO-I - Tender offer statement by Issuer

Nov 13, 2025

SC TO-C

Form SC TO-C - Written communication relating to an issuer or third party

Nov 12, 2025

SC TO-C

Form SC TO-C - Written communication relating to an issuer or third party

Nov 6, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 16, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Mar 16, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Oct 20, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Oct 15, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Oct 3, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 11, 2025

Ownerships

TYPE

HEADLINE

FILED AT

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

May 5, 2023

CORRESP

Form CORRESP - Correspondence

Apr 28, 2023

LETTER

Form UPLOAD - SEC-generated letter

Apr 20, 2023

EFFECT

Form EFFECT - Notice of Effectiveness

Dec 7, 2018

CT ORDER

Form CT ORDER - Confidential treatment order

Dec 4, 2018

CORRESP

Form CORRESP - Correspondence

Dec 4, 2018

Moderna, Inc. MRNA · SEC Filings